Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Within the body weight range of 60 to 100 kilograms, inclusive (for the pivotal cohort \[Part 2\] only)~* Within body mass index (BMI) range 18.0 to 30.0 kilograms per square meter (kg/m\^2), inclusive~* In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs~* Females will be non-pregnant, non-lactating, and either postmenopausal (at least 12 months of non-therapy-induced amenorrhea)/surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days prior to enrolment, or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration~* Males will either be sterile or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration~Exclusion Criteria:~* Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab)~* Any prior treatment with anti-mucosal addressin cell adhesion molecule 1 (anti-MAdCAM-1) agents~* Any prior treatment with rituximab~* Received intravenous corticosteroids within 30 days prior to Screening~* Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab) within 12 months prior to randomization~* Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil)~* Chronic nonsteroidal anti-inflammatory drug (NSAID) use~* Use of any prescription medications/products within 14 days prior to Check in (Day -1)~* History of demyelinating disease~* Neurological conditions or diseases~* History of cancer~* History of alcoholism or drug addiction within less than (\<) 1 year prior to Screening~* History of active or latent tuberculosis (TB), regardless of treatment history~* History of recurrent opportunistic infections and/or history of severe disseminated viral infections~* Positive for human immunodeficiency virus (HIV) antibody~* Any current or recent signs or symptoms of infection~* Pregnant or lactating~* Hospitalized within 4 weeks prior to and during Screening~* History of organ transplant~* Presence of skin rash at Screening or history of other skin disorders~* Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part 1: Etrolizumab AI (Type: EXPERIMENTAL): Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
- Part 1: Etrolizumab PFS-NSD (Type: ACTIVE_COMPARATOR): Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
- Part 2: Etrolizumab AI (Type: EXPERIMENTAL): Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
- Part 2: Etrolizumab PFS-NSD (Type: ACTIVE_COMPARATOR): Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete